Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2016

01-06-2016 | Original Article

Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies

Authors: Walid S. Hamadou, Violaine Bourdon, Pascaline Gaildrat, Sawsen Besbes, Aurélie Fabre, Yosra B. Youssef, Haifa Regaieg, Mohamed A. Laatiri, François Eisinger, Véronique Mari, Paul Gesta, Hélène Dreyfus, Valérie Bonadona, Catherine Dugast, Hélène Zattara, Laurence Faivre, Saloua Yacoub Jemni, Testsuro Noguchi, Abderrahim Khélif, Hagay Sobol, Zohra Soua

Published in: Annals of Hematology | Issue 7/2016

Login to get access

Abstract

Familial aggregation of hematological malignancies has been reported highlighting inherited genetic predisposition. In this study, we targeted four candidate genes: JAK2 and RUNX1 genes assuring a prominent function in hematological process and CBL and NPM1 as proto-oncogenes. Their disruption was described in several sporadic hematological malignancies. The aim of this study is to determine whether JAK2, CBL, RUNX1, and NPM1 germline genes mutations are involved in familial hematological malignancies. Using direct sequencing, we analyzed JAK2 (exons 12 and 14); CBL (exons 7, 8 and 9); NPM1 (exon 12) and the entire RUNX1 in 88 independent families belonging to Tunisian and French populations. Twenty-one sporadic acute leukemias were included in this study. We reported a heterozygous intronic c.1641 + 6 T > C JAK2 variant (rs182123615) found in two independent familial cases diagnosed with gastric lymphoma and Hodgkin lymphoma. The in silico analysis suggested a potential impact on splicing, but the functional splicing minigene reporter assay on rs182123615 variant showed no aberrant transcripts. In one sporadic acute myeloblastic leukemia, we reported an insertion 846 in. TGTT in exon 12 of NPM1 gene that may impact the normal reading frame. The rs182123615 JAK2 variant was described in several contexts including myeloproliferative neoplasms and congenital erythrocytosis and was supposed to be pathogenic. Through this current study, we established the assessment of pathogenicity of rs182123615 and we classified it rather as rare polymorphism.
Literature
1.
Segel GB, Lichtman MA (2004) Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 32(1):246–261CrossRefPubMed
2.
Goldin LR, Landgren O, McMaster ML, Gridley G, Hemminki K, Li X et al (2005) Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 14(10):2402–2408CrossRefPubMed
3.
Langabeer SE, Haslam K, Linders J, Percy MJ, Conneally E, Hayat A et al (2014) Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquiredJAK2, CALR and MPL mutations. Fam Cancer 13(4):659–663CrossRefPubMed
4.
5.
Lv J, Wang X, Liu SY, Liang PF, Feng M, Zhang LL, Xu AP (2015) Protective effect of Fenofibrate in renal ischemia reperfusion injury: involved in suppressing kinase 2 (JAK2)/transcription 3 (STAT3)/p53 signaling activation. Pathol Biol 63(6):236–242CrossRefPubMed
6.
Ito Y (2004) Oncogenic potential of the RUNX gene family: ‘overview’. Oncogene 23(24):4198–4208CrossRefPubMed
7.
Kurokawa M (2006) AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis. Int J Hematol 84(2):136–142CrossRefPubMed
8.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106(4):1207–1216CrossRefPubMedPubMedCentral
9.
Berger R (2006) A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders. Pathol Biol 54(4):182–186CrossRefPubMed
10.
Inami M, Yamaguchi H, Hasegawa S, Mitamura Y, Kosaka F, Kobayashi A et al (2008) Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia. Leukemia 22(1):216CrossRefPubMed
11.
Morgan KJ, Gilliland DG (2008) A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 59:213–222CrossRefPubMed
12.
Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL et al (2000) High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96(8):2862–2871PubMed
13.
Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103(6):2316–2324CrossRefPubMed
14.
Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM et al (2008) Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112(12):4639–4645CrossRefPubMed
15.
Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904–912CrossRefPubMed
16.
Swaminathan G, Tsygankov AY (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209(1):21–43CrossRefPubMed
17.
Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H et al (2008) 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygousmutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68(24):10349–10357CrossRefPubMedPubMedCentral
18.
Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114(9):1859–1863CrossRefPubMedPubMedCentral
19.
Pérez B, Mechinaud F, Galambrun C, Ben Romdhane N, Isidor B, Philip N et al (2010) Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 47(10):686–691CrossRefPubMed
20.
Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E et al (1999) Detection of normal and chimeric nucleophosmin in human cells. Blood 93(2):632–642PubMed
21.
Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6(7):493–505CrossRefPubMed
22.
Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R et al (2009) A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 23(3):501–509CrossRefPubMed
23.
Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF et al (2007) Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 21(5):1099–1103PubMed
24.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266CrossRefPubMed
25.
Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M et al (2007) lt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110(3):1004–1012CrossRefPubMed
26.
Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ et al (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110(3):1022–1026CrossRefPubMedPubMedCentral
27.
Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 27(4):171–181CrossRefPubMedPubMedCentral
28.
Bains A, Luthra R, Medeiros LJ, Zuo Z (2011) FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 135(1):62–71CrossRefPubMed
29.
Gaildrat P, Killian A, Martins A, Tournier I, Frébourg T, Tosi M (2010) Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants. Methods Mol Biol 653:249–257CrossRefPubMed
30.
Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B et al (2012) RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a Poor prognosis and upregulation of lymphoid genes. Haematologica 97(12):1909–1915CrossRefPubMedPubMedCentral
31.
Gosse G, Celton M, Lamontagne V, Forest A, Wilhelm BT (2015) Whole genome and transcriptome analysis of a novel AML cell line with a normal karyotype. Leuk Res 39(7):709–718CrossRefPubMed
32.
Browne G, Taipaleenmäki H, Bishop NM, Madasu SC, Shaw LM, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2015) Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J Cell Physiol 230(10):2522–32CrossRefPubMed
33.
Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U (2007) Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia 21(2):366–373CrossRefPubMed
34.
Marcinkowska-Swojak M, Handschuh L, Wojciechowski P, Goralski M, Tomaszewski K, Kazmierczak M et al (2016) Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification. Mutat Res 4:14–26CrossRef
35.
dos Santos MT, Mitne-Neto M, Miyashiro K, Chauffaille Mde L, Rizzatti EG (2014) Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluationof patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms. J Clin Pathol 67(2):176–184CrossRefPubMedPubMedCentral
36.
Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C et al (2013) Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). Eur J Haematol 91(4):361–370PubMed
37.
El Abed R, Bourdon V, Voskoboinik I, Omri H, Youssef YB, Laatiri MA et al (2011) Molecular study of the perforin gene in familial hematological malignancies. Hered Cancer Clin Pract 9(1):9CrossRefPubMedPubMedCentral
Metadata
Title
Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies
Authors
Walid S. Hamadou
Violaine Bourdon
Pascaline Gaildrat
Sawsen Besbes
Aurélie Fabre
Yosra B. Youssef
Haifa Regaieg
Mohamed A. Laatiri
François Eisinger
Véronique Mari
Paul Gesta
Hélène Dreyfus
Valérie Bonadona
Catherine Dugast
Hélène Zattara
Laurence Faivre
Saloua Yacoub Jemni
Testsuro Noguchi
Abderrahim Khélif
Hagay Sobol
Zohra Soua
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2678-y

Other articles of this Issue 7/2016

Annals of Hematology 7/2016 Go to the issue

Original Article

Communication during haematological consultations; patients’ preferences and professionals’ performances

Original Article

Correlation between ‘H’ blood group antigen and Plasmodium falciparum invasion

Original Article

Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia

Letter to the Editor

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib

Original Article

Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease

Letter to the Editor

Influence of single nucleotide polymorphisms in the BCL11A and HBS1L-MYB gene on the HbF levels and clinical severity of sickle cell anaemia patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits